Santen Oy

Company snapshot

SANTEN OY is a pharma organization headquartered in TAMPERE, FI. Primary therapeutic focus areas include Acquired Blepharoptosis, Diabetic Macular Edema, Fuchs Endothelial Corneal Dystrophy (FECD). NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (2), phase 2 (1).

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Santen Oy. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Santen Oy.

1. Jun 8, 2026 Clinical update

   101380003SA — Phase 3

2. Jun 8, 2026 Clinical update

   101090401IN — Phase 2

3. Jun 8, 2026 Clinical update

   Betamethasone Microsphere (DE-102） Low Dose — Phase 3

View all clinical trial activity →

• What is Santen Oy?

  SANTEN OY is a pharma organization headquartered in TAMPERE, FI. Primary therapeutic focus areas include Acquired Blepharoptosis, Diabetic Macular Edema, Fuchs Endothelial Corneal Dystrophy (FECD). NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record

• Is Santen Oy publicly traded?

  Santen Oy appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Santen Oy develop or market?

  We link 8 drug profile(s) where Santen Oy is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/santen-oy#company-drugs.

• What are the latest developments for Santen Oy?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Santen Oy focus on?

  Santen Oy focuses on Acquired Blepharoptosis, Diabetic Macular Edema, Fuchs Endothelial Corneal Dystrophy (FECD) based on our analysis of their pipeline programs and drug development activities.